EP Patent

EP2714011B1 — Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current

Assigned to Signpath Pharma Inc · Expires 2018-01-31 · 8y expired

What this patent protects

Patent listed against sotalol-hydrochloride.

Drugs covered by this patent

sotalol-hydrochloride (SOTALOL HYDROCHLORIDE)

Patent Metadata

Patent number: EP2714011B1
Jurisdiction: EP
Classification: —
Expires: 2018-01-31
Drug substance claim: No
Drug product claim: No
Assignee: Signpath Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.